Dietary Fatty Acid Oxidation is Decreased in Non-Alcoholic Fatty Liver Disease: A Palmitate Breath Test Study

af Naguib, Gihan, Morris, Nevitt, Yang, Shanna, Fryzek, Nancy, Haynes-Williams, Vanessa, Huang, Wen Chun A., Norman-Wheeler, Jaha, Rotman, Yaron
Udgivet i Liver Int (2019)

Understanding early serum hepatitis D virus and HBsAg kinetics during pegylated interferon-alfa therapy via mathematical modeling

af Guedj, Jeremie, Rotman, Yaron, Cotler, Scott J., Koh, Christopher, Schmid, Peter, Albrecht, Jeff, Haynes-Williams, Vanessa, Liang, Jake T., Hoofnagle, Jay H., Heller, Theo, Dahari, Harel
Udgivet i Hepatology (2014)

Long Term Outcome of Chronic Hepatitis C after Sustained Virological Response to Interferon-Based Therapy

af Koh, Christopher, Heller, Theo, Haynes-Williams, Vanessa, Hara, Koji, Zhao, Xiongce, Feld, Jordan J., Kleiner, David E., Rotman, Yaron, Ghany, Marc G., Liang, T. Jake, Hoofnagle, Jay H.
Udgivet 2013

Long term therapy of chronic delta hepatitis with peginterferon alfa

af Heller, Theo, Rotman, Yaron, Koh, Christopher, Clark, Shauna, Haynes-Williams, Vanessa, McBurney, Rebecca, Schmid, Peter, Albrecht, Jeffrey, Kleiner, David E., Ghany, Marc G., Liang, T. Jake, Hoofnagle, Jay H.
Udgivet i Aliment Pharmacol Ther (2014)

Liver Injury is Associated with Mortality in Sickle Cell Disease

af Feld, Jordan J., Kato, Gregory J., Koh, Christopher, Shields, Tammy, Hildesheim, Mariana, Kleiner, David E., Taylor, James G, Sandler, Netanya G., Douek, Daniel, Haynes-Williams, Vanessa, Nichols, James S., Hoofnagle, Jay H., Liang, T. Jake, Gladwin, Mark T., Heller, Theo
Udgivet i Aliment Pharmacol Ther (2015)

Ribavirin improves early responses to peginterferon through enhanced interferon signaling

af Feld, Jordan J., Lutchman, Glen A., Heller, Theo, Hara, Koji, Pfeiffer, Julie K., Leff, Richard D, Meek, Claudia, Rivera, Maria, Ko, Myung, Koh, Christopher, Rotman, Yaron, Ghany, Marc G., Haynes-Williams, Vanessa, Neumann, Avidan U., Liang, T. Jake, Hoofnagle, Jay H.
Udgivet 2010

Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial

af Koh, Christopher, Canini, Laetitia, Dahari, Harel, Zhao, Xiongce, Uprichard, Susan L, Haynes-Williams, Vanessa, Winters, Mark A, Subramanya, Gitanjali, Cooper, Stewart L, Pinto, Peter, Wolff, Erin F, Bishop, Rachel, Han, Ma Ai Thanda, Cotler, Scott J, Kleiner, David E, Keskin, Onur, Idilman, Ramazan, Yurdaydin, Cihan, Glenn, Jeffrey S, Heller, Theo
Udgivet i Lancet Infect Dis (2015)